TRANEXAMIC ACID TABLETS

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

TRANEXAMIC ACID

Предлага се от:

STERIMAX INC

АТС код:

B02AA02

INN (Международно Name):

TRANEXAMIC ACID

дозиране:

500MG

Лекарствена форма:

TABLET

Композиция:

TRANEXAMIC ACID 500MG

Начин на приложение:

ORAL

Броя в опаковка:

10

Вид предписание :

Prescription

Терапевтична област:

HEMOSTATICS

Каталог на резюме:

Active ingredient group (AIG) number: 0114760001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2013-01-31

Данни за продукта

                                Tranexamic Acid Tablets (Tranexamic Acid Tablets)
Page 1 of 24
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRANEXAMIC ACID TABLETS
(Tranexamic Acid Tablets)
Tablet, 500 mg, Oral
Mfr. Std
Antifibrinolytic Agent
Submission Control No.: 260438
SteriMax Inc.
2770 Portland Drive
Oakville, ON
L6H 6R4
Date of Initial Authorization:
December 3, 2015
Date of Revision:
July 5, 2022
Tranexamic Acid Tablets (Tranexamic Acid Tablets)
Page 2 of 24
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
07/2022
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.................................................................................................
2
TABLE OF CONTENTS
......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics...................................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1
Dosing Considerations
...............................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment.............................................................
5
4.5
Missed Dose
.................................................................................................
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 05-07-2022

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите